代谢物α-甲酸通过脱甲基酶TET2诱导AIM2-依赖的PANoptosis
Yi Li1,2, Qing Tu1,2, Chenchen Liu1,2
1Department of Anesthesiology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 201620, China.
阿尔法-谷氨酸 (α-KG) 通过激活AIM2-PANoptosome通路,驱动炎症和败血症中的细胞死亡. 针对涉及TET2的这种途径,为败血症提供了一种新的治疗策略.
科学领域:
- 免疫代谢过程中的免疫代谢.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 败血症的发病原因
背景情况:
- 阿尔法-谷氨酸 (α-KG) 是三碳酸循环中的一个关键代谢物.
- 传统上被认为是抗炎药,其在败血症中的作用被重新评估.
- 在败血症患者中观察到α-KG水平升高.
研究的目的:
- 研究α-KG在败血症引起的炎症和细胞死亡中的作用.
- 阐明将α-KG与炎症反应联系起来的分子机制.
- 在这个途径中识别潜在的治疗点.
主要方法:
- 来自败血症患者的临床样本的分析.
- 使用细胞透性α-KG衍生物和抑制剂的败血症实验模型.
- 评估巨细胞死亡,组织损伤和炎症标志物.
- 通过遗传和药理干预来研究α-KG/TET2/AIM2信号轴.
主要成果:
- α-KG会加剧LPS诱导的组织损伤和炎症性巨细胞死亡.
- α-KG增强了TET2活性,导致AIM2表达和PANoptosome组装的增加.
- 抑制IDH1,TET2或删除AIM2可以防止败血症引起的病理.
- 一个新的α-KG/TET2/AIM2信号轴驱动炎症性细胞死亡在败血症被确定.
结论:
- α-KG在败血症中起到关键的免疫代谢检查点的作用.
- 该途径涉及TET2介导的AIM2表达的表观遗传控制.
- 向α-KG/TET2/AIM2轴为败血症提供了一个潜在的治疗策略.
更多相关视频
08:34An Engineered Split-TET2 Enzyme for Chemical-inducible DNA Hydroxymethylation and Epigenetic Remodeling
Published on: December 18, 2017
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
相关概念视频
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
PI3K/mTOR/AKT Signaling Pathway
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
